Anaplastic thyroid carcinoma: Palliation or treatment?

Current Opinion in Otolaryngology and Head and Neck Surgery

Volumn 19, Issue 2, 2011, Pages 113-118

  Wein, Richard O ^a   Weber, Randal S ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

anaplastic thyroid carcinoma; extrathyroidal spread; locally invasive thyroid carcinoma; undifferentiated thyroid cancer

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; 7 HYDROXYSTAUROSPORINE; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; HISTONE DEACETYLASE INHIBITOR; MEVINOLIN; NAVELBINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; SUNITINIB;

ANAPLASTIC CARCINOMA; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; HUMAN; LOW DRUG DOSE; MOLECULAR BIOLOGY; PATHOGENESIS; PATIENT CARE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; THYROID CARCINOMA;

CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; NEOPLASM STAGING; PALLIATIVE CARE; PROGNOSIS; QUALITY OF LIFE; RADIOTHERAPY, ADJUVANT; THYROID NEOPLASMS;

EID: 79953865811     PISSN: 10689508     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOO.0b013e328343af3d     Document Type: Review

References (30)

1. Pichardo-Lowden A, Durvesh S, Douglas S, et al. Anaplastic thyroid carcinoma in a young woman: a rare case of survival. Thyroid 2009; 19:775-779.
2. Chiacchio S, Lorenzoni A, Boni G, et al. Anaplastic thyroid cancer: prevalence, diagnosis and treatment. Minerva Endocrinol 2008; 33:341-357.
3. Neff RL, Farrar WB, Kloos RT. Anaplastic thyroid cancer. Endocrinol Metab Clin North Am 2008; 37:525-538. (Pubitemid 351711678)
4. Koussis H, Maruzzo M, Scola A, et al. A case of anaplastic thyroid cancer with long-term survival. Anticancer Res 2010; 30:1273-1278. This case report presents a unique patient who experienced a prolonged survival with persistent ATC that ultimately received sequential cycles of six different chemotherapeutics.
5. Broome JT, Gauger PG, Miller BS, Doherty GM. Anaplastic thyroid cancer manifesting as new-onset Horner syndrome. Endocr Pract 2009; 15:563-566.
6. Patel RS, Enepekides DJ, Higgins KM, et al. Cutaneous metastases in one of the youngest reported patients with anaplastic thyroid carcinoma. Thyroid 2009; 19:781-783.
7. Smallridge RC, Copland JA. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol 2010; 22:486-497. This article is one of the most detailed recent reviews of the molecular pathogenesis of ATC. The authors reviewed outcomes from 1771 patients obtained by PubMed review and reviewed the Surveillance, Epidemiology and End-Results (SEER) database.
8. Swaak-Kragten AT, de Wilt JH, Schmitz PI, et al. Multimodality treatment for anaplastic thyroid carcinoma - treament outcome in 75 patients. Radiother Oncol 2009; 92:100-104. This large retrospective series reiterates the importance of multimodality therapy and margin status of surgical resection in patients with ATC. Mentions the use of prophylactic lung irradiation for the risk of future development of pulmonary metastases.
9. Dandekar P, Harmer C, Barbachano Y, et al. Hyperfractionated accelerated radiotherapy (HART) for anaplastic thyroid carcinoma: toxicity and survival analysis. Int J Radiat Oncol Biol Phys 2009; 74:518-521. This report demonstrates the potential significant toxicity associated with hyperfractionated accelerated radiotherapy when used to treat patients with ATC.
10. National Comprehensive Care Network. NCCN clinical practice guidelines in oncology, thyroid carcinoma. National Comprehensive Care Network; 2007: 2:28. http://www.nccn.org/. [Accessed 28 August 2008]
11. Besic N, Hocevar M, Zgajnar J. Lower incidence of anaplastic carcinoma after higher iodination of salt in Slovenia. Thyroid 2010; 20:623-626.
12. Catalano MG, Poli R, Pugliese M, et al. Emerging molecular therapies of advanced thyroid cancer. Mol Aspects Med 2010; 31:215-226. This article provides a detailed review of all of the reported genetic mutations, epigenetic alterations, and targeted therapies in ATC.
13. Marlow LA, D'Innocenzi J, Zhang Y, et al. Detailed molecular fingerprinting of four new anaplastic thyroid carcinoma cell lines and their use for verification of RhoB as a molecular therapeutic target. J Clin Endocrinol Metab 2010; 95: 1-10.
14. Marlow LA, Reynolds LA, Cleland AS, et al. Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth. Cancer Res 2009; 69:1536-1544. This article details the importance of RhoB in the growth inhibition of ATC as it relates to p21 and PPARg.
15. Francipane MG, Eterno V, Spina V, et al. Suppressor of cytokine signaling 3 sensitizes anaplastic thyroid cancer to standard chemotherapy. Cancer Res 2009; 69:6141-6148.
16. Nucera C, Eeckhoute J, Finn S, et al. FOXA1 is a potential oncogene in anaplastic thyroid carcinoma. Clin Cancer Res 2009; 15:3680-3689.
17. Kim TH, Yoo YH, Kang DY, et al. Efficacy on anaplastic thyroid carcinoma of valproic acid alone or in combination with doxorubicin, a synthetic chenodeoxycholic acid derivative, or lactocystin. Int J Oncol 2009; 34:1353-1362.
18. Ralhan R, Cao J, Lim T, et al. EpCAM nuclear localization identifies aggressive thyroid cancer and is a marker for poor prognosis. BMC Cancer 2010; 10:331.
19. Braun J, Hoang-Vu C, Dralle H, Huttelmaier S. Downregulation of microRNAs directs the ENT and invasive potential of anaplastic thyroid carcinomas. Oncogene 2010; 29:4237-4244.
20. Nappi TC, Salerno P, Zitzelsberger H, et al. Identification of Polo-like kinase1 as a potential therapeutic target in anaplastic thyroid carcinoma. Cancer Res 2009; 69:1916-1923.
21. American Joint Cancer Committee. AJCC cancer staging manual. 7th ed. Chicago: AJCC; 2010.
22. Ito Y, Higashiyama T, Hirokawa M, et al. Investigation of the validity of UICC stage grouping of anaplastic carcinoma of the thyroid. Asian J Surg 2009; 32:47-50. This article separates the prognosis of stage IVB ATC patients based on operative respectability in relation to prognosis. Patients incapable of curative resection had outcomes that paralleled stage IVC patients.
23. Higashiyama T, Ito Y, Hirokawa M, et al. Optimal surgical procedure for locally curative surgery in patients with anaplastic thyroid carcinoma: importance of preoperative ultrasonography. Endocr J 2010; 57:763-769. This study suggests that total thyroidectomy may not be necessary for patients with lateralized unifocal ATC.
24. Pudney D, Lau H, Falck V. Clinical experience of the multimodality management of anaplastic thyroid cancer and literature review. Thyroid 2007; 17:1243-1250.
25. Higashiyama T, Ito Y, Hirokawa M, et al. Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid 2010; 20:7-14. This study reports the therapeutic benefit of induction chemotherapy with paclitaxel in patients with stage IVB ATC. Response to induction chemotherapy enabled the potential of curative surgery, and responders achieved longer overall survivals than nonresponders.
26. Pennell NA, Daniels GH, Haddad RI, et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 2008; 18:317-323. (Pubitemid 351415790)
27. Kawada K, Kitagawa K, Kamei S, et al. The feasibility study of docetaxel in patients with anaplastic thyroid cancer. Jpn J Clin Oncol 2010; 40:596-599.
28. Mooney CJ, Nagaiah G, Wasman JK, et al. A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serumsoluble intracellular adhesion molecule-1 with outcome. Thyroid 2009; 19:233-240. This article reports the results of one of the first clinical trials utilizing this new class of microtubule inhibitors that possess vascular disrupting effects.
29. Hogan T, Jing JY, Williams HJ, et al. Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib. J Oncol Pharm Pract 2009; 15:111-117.
30. Noguchi H, Yamashita H, Murakami T, et al. Successful treatment of anaplastic carcinoma with a combination of oral valproic acid, chemotherapy, radiation and surgery. Endocr J 2009; 56:245-249.